ESC 2026: Evidence supporting SGLT2 inhibitors and finerenone in heart failure grows - Pharmaceutical Technology

Several treatment guidelines worldwide recommend the use of SGLT2 inhibitors as a treatment for all types of heart failure. Several treatment guidelines worldwide recommend the use of SGLT2 inhibitors as a treatment for all types of heart failure. The European Society of Cardiology Congress 2026 took place 28-31 August in Munich, Germany. Scientific presentations indicated a growing understanding of the use of SGLT2 inhibitors and the mineralocorticoid receptor antagonist finerenone for the treatment and management of heart failure. Image credit: [hydebrink]/Shutterstock.com. Image is from ESC 2018, which also took place in Munich. Unlock FREE Access to Premium Content ​Discover exclusive…

Source: Pharmaceutical Technology